PortfoliosLab logo
DAVE vs. SRPT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DAVE and SRPT is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

DAVE vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%100.00%December2025FebruaryMarchAprilMay
-66.60%
-13.15%
DAVE
SRPT

Key characteristics

Sharpe Ratio

DAVE:

1.45

SRPT:

-0.84

Sortino Ratio

DAVE:

2.34

SRPT:

-1.25

Omega Ratio

DAVE:

1.29

SRPT:

0.82

Calmar Ratio

DAVE:

1.42

SRPT:

-0.71

Martin Ratio

DAVE:

5.56

SRPT:

-1.65

Ulcer Index

DAVE:

23.90%

SRPT:

31.22%

Daily Std Dev

DAVE:

92.14%

SRPT:

61.44%

Max Drawdown

DAVE:

-99.01%

SRPT:

-98.17%

Current Drawdown

DAVE:

-77.11%

SRPT:

-64.38%

Fundamentals

Market Cap

DAVE:

$1.40B

SRPT:

$6.24B

EPS

DAVE:

$4.19

SRPT:

$2.34

PE Ratio

DAVE:

24.99

SRPT:

27.14

PS Ratio

DAVE:

4.03

SRPT:

3.28

PB Ratio

DAVE:

7.63

SRPT:

4.08

Total Revenue (TTM)

DAVE:

$273.45M

SRPT:

$1.49B

Gross Profit (TTM)

DAVE:

$226.28M

SRPT:

$1.21B

EBITDA (TTM)

DAVE:

$33.69M

SRPT:

$251.31M

Returns By Period

In the year-to-date period, DAVE achieves a 20.51% return, which is significantly higher than SRPT's -47.64% return.


DAVE

YTD

20.51%

1M

47.95%

6M

178.07%

1Y

132.06%

5Y*

N/A

10Y*

N/A

SRPT

YTD

-47.64%

1M

16.96%

6M

-48.27%

1Y

-52.37%

5Y*

-12.33%

10Y*

15.84%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DAVE vs. SRPT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAVE
The Risk-Adjusted Performance Rank of DAVE is 8888
Overall Rank
The Sharpe Ratio Rank of DAVE is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of DAVE is 8989
Sortino Ratio Rank
The Omega Ratio Rank of DAVE is 8686
Omega Ratio Rank
The Calmar Ratio Rank of DAVE is 8989
Calmar Ratio Rank
The Martin Ratio Rank of DAVE is 8787
Martin Ratio Rank

SRPT
The Risk-Adjusted Performance Rank of SRPT is 77
Overall Rank
The Sharpe Ratio Rank of SRPT is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 88
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 88
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 88
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DAVE vs. SRPT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current DAVE Sharpe Ratio is 1.45, which is higher than the SRPT Sharpe Ratio of -0.84. The chart below compares the historical Sharpe Ratios of DAVE and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.005.0010.00December2025FebruaryMarchAprilMay
1.45
-0.84
DAVE
SRPT

Dividends

DAVE vs. SRPT - Dividend Comparison

Neither DAVE nor SRPT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DAVE vs. SRPT - Drawdown Comparison

The maximum DAVE drawdown since its inception was -99.01%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for DAVE and SRPT. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%December2025FebruaryMarchAprilMay
-77.11%
-61.15%
DAVE
SRPT

Volatility

DAVE vs. SRPT - Volatility Comparison

Dave Inc. (DAVE) has a higher volatility of 25.31% compared to Sarepta Therapeutics, Inc. (SRPT) at 22.68%. This indicates that DAVE's price experiences larger fluctuations and is considered to be riskier than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%December2025FebruaryMarchAprilMay
25.31%
22.68%
DAVE
SRPT

Financials

DAVE vs. SRPT - Financials Comparison

This section allows you to compare key financial metrics between Dave Inc. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M600.00M700.00MAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
100.84M
658.41M
(DAVE) Total Revenue
(SRPT) Total Revenue
Values in USD except per share items

DAVE vs. SRPT - Profitability Comparison

The chart below illustrates the profitability comparison between Dave Inc. and Sarepta Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
93.8%
79.9%
(DAVE) Gross Margin
(SRPT) Gross Margin
DAVE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Dave Inc. reported a gross profit of 94.56M and revenue of 100.84M. Therefore, the gross margin over that period was 93.8%.

SRPT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 526.11M and revenue of 658.41M. Therefore, the gross margin over that period was 79.9%.

DAVE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Dave Inc. reported an operating income of 20.99M and revenue of 100.84M, resulting in an operating margin of 20.8%.

SRPT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of 161.68M and revenue of 658.41M, resulting in an operating margin of 24.6%.

DAVE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Dave Inc. reported a net income of 16.81M and revenue of 100.84M, resulting in a net margin of 16.7%.

SRPT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of 159.05M and revenue of 658.41M, resulting in a net margin of 24.2%.